Sandip P. Patel, MD

Panelists discuss how final thoughts emphasize the importance of ongoing research, collaborative care, and adapting treatment strategies to improve patient outcomes in the evolving therapy landscape.

Panelists discuss how surgical perspectives on durvalumab emphasize its role in enhancing patient outcomes, informing surgical decision-making, and integrating immunotherapy into comprehensive treatment plans.

Panelists discuss how considerations for treatment approach encompass patient-specific factors, treatment modalities, and the integration of emerging therapies to optimize outcomes in clinical practice.

Panelists discuss how the results and outcomes of the AEGEAN trial reveal significant findings regarding the treatment’s effectiveness and safety, shaping future approaches in patient care and management.

Panelists discuss how the importance of AEGEAN approval lies in its potential to enhance patient treatment options, paving the way for improved outcomes and informing clinical practice in the field.

Panelists discuss how the AEGEAN trial provides critical insights into the efficacy and safety of new therapeutic approaches, highlighting its design, key findings, and implications for future treatment strategies.

Sandip P. Patel, MD, offers advice to fellow oncologists and highlights unmet needs and future directions in the treatment of patients with non–small cell lung cancer.

A medical oncologist reviews the efficacy and safety outcomes from the ADAURA trial investigating osimertinib in resected EGFR-mutated NSCLC and discusses how biomarkers inform treatment selection.

Turning the focus to EGFR inhibitors, Sandip P. Patel, MD, discusses their mechanism action and the improved toxicity profile of next-generation inhibitors.

Expert perspectives on treating patients with non–small cell lung cancer, with a focus on treatment goals and patient factors that inform clinical decision-making and sequencing considerations.

A medical oncologist offers his initial impressions of the patient profile of a 60-year-old with early-stage NSCLC and discusses biomarker testing practices, highlighting types of testing and challenges.

Sandip P. Patel, MD, reviews the case of a 60-year-old woman with early-stage non–small cell lung cancer (NSCLC).

Expert Sandip Patel, MD, looks toward the promising future of lung cancer research, including targeted therapies, novel immunotherapy approaches, and the importance of biomarkers in guiding treatment decisions.

Insight into key patient characteristics and considerations in determining the optimal approach for treating metastatic non-small cell lung cancer, including the role of chemotherapy, immunotherapy, and targeted therapy.

Sandip Patel, MD, discusses the durability of immunotherapy responses, updated survival data from clinical trials, and considerations for patients in the metastatic lung cancer setting.

A concise review of five-year updates from pivotal immunotherapy studies in lung cancer, highlighting the durability of responses and treatment options for high-risk disease

Expert perspectives on the significance and limitations of PD-L1 testing in non-small cell lung cancer and the importance of integrating genomic characterization for informed treatment choices.

Key insight into ongoing challenges and unmet needs in non-small cell lung cancer treatment, including specific patient populations and potential solutions through clinical trials.

Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.